Compare Novartis AG (NVS) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Novartis AG trades at $139.89 (market cap $262.64B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $38.55. The key difference: Novartis AG pays a 3.44% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Novartis AG is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVS | QDTY | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $46.71 |
52-Week Low | $121.80 | $36.57 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
QDTY trades at $39.07, up 0.12% on the day, with a bearish technical signal driven by moving averages. The stock exhibits weekly dividend distributions, yet key valuation and profitability ratios are unavailable, limiting fundamental clarity. Recent news highlights consistent dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook hinges on forthcoming financial disclosures to assess sustainability; risks include reliance on dividend strategy amid missing fundamentals. Investors face uncertainty without earnings or revenue data, requiring caution until corporate performance metrics are published.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
